The global Myasthenia Gravis (MG) treatment market is projected to exhibit strong growth through the forecast period. The MG treatment market is driven by a strong pipeline comprising of around 19 drug candidates, increased focus on R&D of biologics, growing awareness and adoption of novel therapies, favorable investment scenario, healthcare facilities, and reimbursement policies in developed economies. Furthermore, emerging targeted therapies and symptom based therapies are believed to present significant market opportunity in the treatment of myasthenia gravis.
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder that leads to varying degrees of skeletal muscle weakening in the eyes, face, and throat. This rare disease is caused due to communication loss between the nerve cells and muscles causing difficulties in the relaxation and contraction of muscles controlling the eyes and eyelids, speaking, chewing, and facial expressions. Myasthenia gravis is the most common type of neuromuscular disorder according to the Myasthenia Gravis Foundation of America. In the U.S., the prevalence of myasthenia gravis is around 14 - 20 cases per 100,000 people.
Myasthenia gravis remains an incurable disease despite the current treatment options that include surgery, intravenous therapies, autologous stem cell transplants, and medications such as cholinesterase inhibitors and immunosuppressants. Some of the drugs used for MG treatment are Mestinon and immunotherapeutic agents such as Imuran, Neoral,Solaris, and CellCept.The key players for myasthenia gravis treatment market include: Novartis Pharmaceuticals Corporation, Grifols SA, Pfizer, GlaxoSmithKline plc, Bristol-Myers Squibb Company, AbbVie Inc., Valeant Pharmaceuticals International, F. Hoffmann Roche La Ltd., RPG Life Sciences, Biogen Inc., and others.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."